LABORATORY CORP AMER HLDGS shareholders Q2 2022

LABORATORY CORP AMER HLDGS's ticker is LH and the CUSIP is 50540R409. A total of 960 filers reported holding LABORATORY CORP AMER HLDGS in Q2 2022. The put-call ratio across all filers is 0.63 and the average weighting 0.3%.

LABORATORY CORP AMER HLDGS shareholders Q2 2022
Name	Shares	Value	Weighting ↓
SPEECE THORSON CAPITAL GROUP INC	56,300	$13,194,000	3.11%
Endurant Capital Management LP	34,718	$8,137,000	2.86%
NEEDHAM INVESTMENT MANAGEMENT LLC	60,763	$14,240,000	2.66%
AMI ASSET MANAGEMENT CORP	178,922	$41,932,000	2.66%
Ironvine Capital Partners, LLC	89,952	$21,081,000	2.59%
Eukles Asset Management	17,106	$4,009,000	2.54%
EUBEL BRADY & SUTTMAN ASSET MANAGEMENT INC	52,530	$12,311,000	2.46%
FAIRFIELD, BUSH & CO.	17,673	$4,142,000	2.44%
Mondrian Investment Partners LTD	464,643	$108,894,000	2.27%
FORTE CAPITAL LLC /ADV	55,065	$12,905,000	2.25%
Garrison Asset Management, LLC	13,896	$3,257,000	2.18%
Heron Bay Capital Management	15,118	$3,543,000	2.15%
DAVIDSON INVESTMENT ADVISORS	102,745	$24,079,000	2.05%
White Pine Investment CO	21,816	$5,113,000	2.02%
New Potomac Partners, LLC	10,579	$2,479,000	1.99%
Baltimore-Washington Financial Advisors, Inc.	74,343	$17,423,000	1.86%
CARDEROCK CAPITAL MANAGEMENT INC	18,425	$4,318,000	1.80%
XXEC, Inc.	9,533	$2,234,000	1.78%
Ariel Investments	756,683	$177,336,000	1.77%
Stack Financial Management, Inc	73,797	$17,295,000	1.72%

About LABORATORY CORP AMER HLDGS

Laboratory Corp Amer Hldgs, also known as LabCorp, is a leading healthcare diagnostics company that provides laboratory testing services to patients, physicians, and other healthcare providers. The company operates a network of over 2,000 patient service centers and offers a broad range of clinical laboratory tests, including genetic testing, oncology testing, and infectious disease testing.

LabCorp has been at the forefront of the fight against COVID-19, providing testing services to help diagnose and monitor the spread of the virus. The company has also been working on developing new tests to detect COVID-19 variants and has been collaborating with other healthcare organizations to improve testing capabilities.

In addition to its COVID-19 efforts, LabCorp has been expanding its services through strategic acquisitions. In 2020, the company acquired two leading contract research organizations, Covance and Chiltern, to enhance its drug development capabilities. This move has positioned LabCorp as a major player in the pharmaceutical industry, providing end-to-end solutions for drug development and clinical trials.

Despite the challenges posed by the pandemic, LabCorp has continued to deliver strong financial results. In the first quarter of 2021, the company reported revenue of $3.9 billion, an increase of 52% compared to the same period in the previous year. LabCorp's CEO, Adam Schechter, attributed the strong performance to the company's focus on innovation and its ability to adapt to changing market conditions.

Overall, LabCorp's commitment to innovation and its strong financial performance make it a promising investment opportunity for those looking to invest in the healthcare industry.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

External links

This page lists LABORATORY CORP AMER HLDGS's shareholders in Q2 2022. To view LABORATORY CORP AMER HLDGS's shareholder history, click here.